Alliance Global Partners downgraded Matinas BioPharma (MTNB) to Neutral from Buy without a price target after the company announced that negotiations under the previously disclosed non-binding term sheet regarding marketing rights to its oral formulation of amphotericin B have been terminated by the prospective partner. Matinas has implemented an 80% workforce reduction as a result of this event, the analyst tells investors in a research note. The firm says “this is a material negative event for the company that introduces significant uncertainty.” Alliance Global suspects Matinas “is stretching its runway to try and sell/partner the asset.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on MTNB:
- Matinas BioPharma cut to Hold at Maxim on termination of MAT2203 talks
- Matinas BioPharma downgraded to Hold from Buy at Maxim
- Matinas BioPharma says MAT2203 partnership negotiations terminated
- Matinas BioPharma Slashes Workforce Amid Financial Turmoil
- Biotech Alert: Searches spiking for these stocks today
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
